Monday, August 29, 2005
FDA approves Cymbalta for the treatment of depression
There is a new depression medication that will hit the pharmacy shelves soon. Cymbalta, which is manufactured by Eli Lilly and Company, falls in the SSNRI (serotonin and norepinephrine) class of antidepressants. In clinical studies, the most common side effects were nausea, dry mouth, constipation, decreased appetite, fatigue, sleepiness and increased sweating. However, the FDA warns against all pharmaceutical antidepressants, and requires that all antidepressants carry a "black box warning" to alert patients of the increased risk of suicide while taking antidepressants. There are alternatives to pharmaceutical antidepressants. You might want to look at Deprex, which is highly effective and safe in the treatment of depression.